Heska (NASDAQ:HSKA) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, January 3rd.
Several other research analysts have also recently weighed in on HSKA. Zacks Investment Research cut shares of Heska from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. Aegis reissued a “buy” rating on shares of Heska in a report on Tuesday, December 19th. Raymond James Financial reaffirmed a “buy” rating on shares of Heska in a report on Monday, December 4th. Canaccord Genuity initiated coverage on shares of Heska in a report on Thursday, October 5th. They set a “buy” rating and a $115.00 target price on the stock. Finally, B. Riley lowered their target price on shares of Heska from $96.50 to $93.00 and set a “neutral” rating on the stock in a report on Friday, November 3rd. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $113.30.
Heska (HSKA) opened at $78.48 on Wednesday. Heska has a one year low of $75.21 and a one year high of $115.00. The company has a market cap of $587.25, a PE ratio of 42.44, a PEG ratio of 2.14 and a beta of 0.74.
Heska (NASDAQ:HSKA) last issued its earnings results on Thursday, November 2nd. The medical research company reported $0.40 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.37 by $0.03. The business had revenue of $31.40 million during the quarter, compared to the consensus estimate of $36.10 million. Heska had a net margin of 10.67% and a return on equity of 15.35%. Heska’s revenue was down 6.0% on a year-over-year basis. During the same period last year, the business posted $0.45 EPS. equities research analysts forecast that Heska will post 2.03 EPS for the current year.
In related news, insider Michael J. Mcginley sold 7,826 shares of Heska stock in a transaction that occurred on Wednesday, November 29th. The shares were sold at an average price of $87.14, for a total value of $681,957.64. Following the transaction, the insider now directly owns 106,771 shares of the company’s stock, valued at $9,304,024.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 14.70% of the company’s stock.
Institutional investors have recently modified their holdings of the business. State of Wisconsin Investment Board acquired a new stake in Heska in the second quarter valued at approximately $510,000. Northern Trust Corp lifted its holdings in shares of Heska by 5.7% during the second quarter. Northern Trust Corp now owns 120,060 shares of the medical research company’s stock worth $12,255,000 after purchasing an additional 6,517 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Heska by 31.7% during the second quarter. Vanguard Group Inc. now owns 461,841 shares of the medical research company’s stock worth $47,141,000 after purchasing an additional 111,232 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Heska by 3.7% during the third quarter. Bank of New York Mellon Corp now owns 100,278 shares of the medical research company’s stock worth $8,834,000 after purchasing an additional 3,610 shares during the period. Finally, AJO LP acquired a new position in shares of Heska during the second quarter worth $719,000. Hedge funds and other institutional investors own 80.89% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/13/heska-hska-cut-to-sell-at-bidaskclub.html.
Heska Company Profile
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.